The Complex Relationship Between Clinical Obesity and Heart Failure Authors: Jinxia Zhang, Cheng Liu Published: 2026 ABSTRACT Corresponding AuthorKey Words: cardiovascular risk, clinical obesity, heart failure, metabolic syndrome, mortality Obesity has become one of the biggest public health challenges of the 21st century.1 In the traditional definition of obesity, body mass index (BMI) is commonly used as an assessment criterion. However, despite its convenience, BMI fails to accurately reflect an individual’s fat distribution, fat metabolism function, and metabolic abnormalities triggered by obesity. To overcome this limitation, the Lancet Diabetes & Endocrinology Commission (LDEC) has recognized clinical obesity as an independent disease and proposed a new definition of "clinical obesity,"2 emphasizing the metabolic abnormalities and consequences caused by obesity rather than relying solely on weight or BMI. Clinical Obesity and Heart Failure In recent years, obesity has garnered significant attention within the medical community as a major risk factor for heart failure (HF). However, the relationship between obesity and HF is complex, particularly when considering clinical obesity. In this issue of JACC: Asia, Liu et al,3 using data from the Kailuan Cohort in China, analyzed 99,367 subjects with a median follow-up of 16.0 years and found that clinical obesity was an independent risk factor for the onset of HF. Compared with nonobese individuals, clinically obese individuals had a 63% increased risk of developing new-onset HF (adjusted HR [aHR]: 1.63; 95% CI: 1.49-1.77), with this risk demonstrating a dose-dependent manner to the number of coexisting clinical complications (eg, hypertension, metabolic abnormalities, sleep apnea). This finding underscored that the link between clinical obesity and HF is not merely a matter of body weight but rather the cumulative effect of metabolic dysfunction and multiple clinical comorbidities. Clinical obesity was strongly associated with various forms of HF, particularly HF with midrange ejection fraction (aHR: 2.14; 95% CI: 1.62-2.84). Moreover, with increasing age, the impact of clinical obesity–related HF gradually diminishes. Specifically, in the younger group (<50 years), the risk of clinical obesity–related HF was the highest (aHR: 2.30; 95% CI: 1.85-2.86), indicating that obesity had the most significant impact on HF risk in this age group. Therefore, adopting a comprehensive intervention strategy targeting clinical obesity and its associated clinical complications is crucial for more effectively preventing and treating obesity-related HF, especially among younger and early middle-aged adults. Moreover, the population-attributable risk percentage of clinical obesity for HF risk was 16.7%, whereas the population-attributable risk of clinical obesity-related complications was even higher, reaching 29.3%. This highlighted the significant role that obesity-related clinical complications played in the development of HF, especially when coupled with metabolic syndrome (aHR: 1.83; 95% CI: 1.65-2.02). These findings suggested that targeted interventions focusing on managing the associated clinical complications in clinical obesity individuals can substantially reduce the incidence of HF. “Obesity Paradox” and Clinical Obesity–Related Mortality Risk In the cardiovascular field, the so-called obesity paradox is commonly observed, where some obese individuals with HF have a lower mortality rate compared with individuals of normal weight.4 Studies suggested that obese individuals may gain some protection through fat reserves during illness. However, Liu et al3 also demonstrated that no significant association was found between clinical obesity and all-cause mortality. This finding suggested that although obesity increased the risk of HF, its impact on mortality may be influenced by factors such as metabolic health status and the burden of chronic diseases. It is important to note that the occurrence of the obesity paradox may depend on the composition of the control group, particularly whether it includes individuals with clinical cardiovascular-metabolic–related risk factors.5 Clinical obesity increased the risk of all-cause mortality by 23% compared with nonobese individuals without clinical complications (aHR: 1.23; 95% CI: 1.01-1.51). Therefore, the existence of the obesity paradox warrants re-examination. In clinical practice, we should not rely solely on weight or BMI as the single standard for risk assessment. Instead, greater consideration should be given to multiple dimensions, including metabolic health and comorbidities, to achieve more accurate risk assessments and personalized treatment strategies. At the same time, the population-attributable risk of clinical obesity for mortality risk in the subjects was 0%, whereas the value of clinical obesity–associated complications was 20.8%. Although obesity is 1 factor for the onset of HF, its direct impact on mortality risk is relatively small once HF occurs. The primary factors influencing mortality risk remain the clinical complications associated with clinical obesity, such as hypertension and metabolic dysfunction. Therefore, for patients who have already developed HF, managing hypertension and metabolic syndrome is more critical than focusing solely on obesity. Transition From Preclinical Obesity to Clinical Obesity Liu et al3 observed that during the first 2 years of follow-up, there were no significant differences in survival rates among the nonobese, preclinical obesity, and clinical obesity groups. However, with prolonged follow-up from 2 to 12 years, the mortality risk of the nonobese and clinical obesity groups gradually increased compared with the preclinical obese group. Notably, after approximately 12 years, the mortality risk in the clinical obesity group worsened significantly compared with the nonobese counterparts. Meanwhile, Zahid et al6 also found that in the UK Biobank cohort, one-fourth of individuals transitioned from preclinical obesity to clinical obesity within 12 years. This suggested that although the survival rate of the preclinical obese group was higher, the transition to clinical obesity and its associated complications over time could lead to poorer long-term outcomes. This transition was a cumulative effect that develops over time. Therefore, early identification and appropriate intervention for preclinical obesity to prevent its progression to clinical obesity may significantly improve individual health outcomes, particularly in the prevention and control of cardiovascular disease. The intervention strategies for managing clinical obesity should be personalized and adjusted based on the different stages of obesity.7 For stage I, which is <2 years (optimal intervention period), individuals in the nonobese or preclinical obesity stage should focus on weight control and lifestyle changes to prevent progression to the next stage, whether it be progressing to preclinical obesity or clinical obesity. For stage II, from 2 to 12 years (sustained intervention period), efforts should aim to prevent the transition from preclinical obesity to clinical obesity. Although the mortality risk may not significantly increase during this stage, the risk of developing clinical obesity remains. Therefore, continuous weight management and health behavior interventions can significantly reduce future health risks. Moreover, interventions during this period help delay the onset of clinical obesity, thereby reducing the long-term health burden. For stage, III, defined as >12 years (clinical obesity management and complication treatment period), once the clinical obesity stage is reached, especially during the 4 years before the median follow-up time, the negative impacts of obesity may accelerate. At this stage, interventions should focus on treating related comorbidities, mitigating the long-term health impacts of obesity, and actively managing obesity-related comorbidities. Clinical Application Prospects and Challenges of the LDEC Obesity Definition Although the new definition of clinical obesity proposed by LDEC has theoretical advantages, its application in clinical practice still faces numerous challenges.8 First, accurately assessing the metabolic consequences of obesity using existing diagnostic tools and medical records remains a pressing issue. Although the International Classification of Diseases, 10h Revision, coding system can identify some obesity-related clinical complications, integrating LDEC's clinical criteria with current systems requires further clinical validation and technical support.5,9 Second, the LDEC standard is relatively complex and may increase the workload of health care providers, especially in resource-limited settings.10 Primary health care institutions, in particular, may encounter difficulties in implementing this standard. Therefore, before widespread global adoption, more practical data and technical support are needed to ensure its clinical feasibility. In summary, clinical obesity is not merely a weight issue but a complex combination of various metabolic abnormalities and clinical comorbidities that significantly increase the risk of HF. The new definition of "clinical obesity" helps to more accurately assess the clinical impact of obesity and provides a new theoretical foundation for obesity management. Future research should continue to explore how to combine metabolic health, degree of obesity, and associated complications to develop personalized intervention strategies, thereby minimizing the occurrence of HF and improving patients' quality of life. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References